{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,26]],"date-time":"2024-05-26T20:10:05Z","timestamp":1716754205397},"reference-count":68,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":488,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Dermatol"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1111\/bjd.12954","type":"journal-article","created":{"date-parts":[[2014,5,20]],"date-time":"2014-05-20T03:06:30Z","timestamp":1400555190000},"page":"1015-1020","source":"Crossref","is-referenced-by-count":5,"title":["Interventions for mycosis fungoides: critical commentary on a Cochrane Systematic Review"],"prefix":"10.1093","volume":"170","author":[{"given":"P.A.","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Dermatology; Beth Israel Deaconess Medical Center; Harvard Medical School; 330 Brookline Ave, GZ522 Boston MA 02215 U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Dermatology; Brigham and Women's Hospital; Harvard Medical School; Boston MA U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.E.","family":"Bigby","sequence":"additional","affiliation":[{"name":"Department of Dermatology; Beth Israel Deaconess Medical Center; Harvard Medical School; 330 Brookline Ave, GZ522 Boston MA 02215 U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2014,5,19]]},"reference":[{"key":"10.1111\/bjd.12954-BIB0001|bjd12954-cit-0001","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.ejca.2006.01.025","article-title":"EORTC consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome","volume":"42","author":"Trautinger","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1111\/bjd.12954-BIB0002|bjd12954-cit-0002","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1111\/j.1365-2133.2003.05698.x","article-title":"Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas","volume":"149","author":"Whittaker","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.12954-BIB0003|bjd12954-cit-0003","unstructured":"National Comprehensive Cancer Network (NCCN) NCCN Guidelines Version 1.2013. Mycosis fungoides\/S\u00e9zary syndrome http:\/\/cutaneouslymphoma.stanford.edu\/docs\/nhl_1%202013_MFSS.pdf"},{"key":"10.1111\/bjd.12954-BIB0004|bjd12954-cit-0004","unstructured":"Centre for Evidence-Based Medicine Levels of evidence http:\/\/www.cebm.net\/?o=1025"},{"key":"10.1111\/bjd.12954-BIB0005|bjd12954-cit-0005","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1200\/JCO.2009.27.7665","article-title":"Survival outcomes and prognostic factors in mycosis fungoides\/S\u00e9zary syndrome: validation of the revised International Society for Cutaneous Lymphomas\/European Organisation for Research and Treatment of Cancer staging proposal","volume":"28","author":"Agar","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1111\/bjd.12954-BIB0006|bjd12954-cit-0006","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/archderm.139.7.857","article-title":"Long-term outcome of 525 patients with mycosis fungoides and S\u00e9zary syndrome: clinical prognostic factors and risk for disease progression","volume":"139","author":"Kim","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1111\/bjd.12954-BIB0007|bjd12954-cit-0007","first-page":"504","article-title":"Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients","volume":"136","author":"Doorn","year":"2000","journal-title":"Arch Dermatol"},{"key":"10.1111\/bjd.12954-BIB0008|bjd12954-cit-0008","doi-asserted-by":"crossref","first-page":"5830","DOI":"10.1002\/cncr.27627","article-title":"Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides: a multicenter, retrospective follow-up study from the Italian Group of Cutaneous Lymphomas","volume":"118","author":"Quaglino","year":"2012","journal-title":"Cancer"},{"key":"10.1111\/bjd.12954-BIB0009|bjd12954-cit-0009","doi-asserted-by":"crossref","first-page":"436","DOI":"10.6004\/jnccn.2008.0033","article-title":"Review of the treatment of mycosis fungoides and S\u00e9zary syndrome: a stage-based approach","volume":"6","author":"Horwitz","year":"2008","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1111\/bjd.12954-BIB0010|bjd12954-cit-0010","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1067\/mjd.2002.120911","article-title":"Narrowband UVB phototherapy for early-stage mycosis fungoides","volume":"47","author":"Gathers","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.12954-BIB0011|bjd12954-cit-0011","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1001\/archderm.134.8.949","article-title":"Topical corticosteroids for mycosis fungoides. Experience in 79 patients","volume":"134","author":"Zackheim","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1111\/bjd.12954-BIB0012|bjd12954-cit-0012","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.ijrobp.2012.05.034","article-title":"Outcome of patients treated with a single-fraction dose of palliative radiation for cutaneous T-cell lymphoma","volume":"85","author":"Thomas","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1111\/bjd.12954-BIB0013|bjd12954-cit-0013","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/j.1468-3083.2009.03500.x","article-title":"Efficacy of narrowband UVB vs. PUVA in patients with early-stage mycosis fungoides","volume":"24","author":"Ponte","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/bjd.12954-BIB0014|bjd12954-cit-0014","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/archderm.139.2.165","article-title":"Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience","volume":"139","author":"Kim","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1111\/bjd.12954-BIB0015|bjd12954-cit-0015","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/archdermatol.2011.98","article-title":"The Stanford University experience with conventional-dose, total skin electron-beam therapy in the treatment of generalized patch or plaque (T2) and tumor (T3) mycosis fungoides","volume":"147","author":"Navi","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1111\/bjd.12954-BIB0016|bjd12954-cit-0016","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/S0190-9622(85)70205-8","article-title":"Intralesional interferon in the treatment of early mycosis fungoides","volume":"13","author":"Wolff","year":"1985","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.12954-BIB0017|bjd12954-cit-0017","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/2013.jamadermatol.541","article-title":"Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides","volume":"149","author":"Lessin","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1111\/bjd.12954-BIB0018|bjd12954-cit-0018","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1001\/jama.1972.03210090052026","article-title":"Complete regressions of mycosis fungoides with topical mechlorethamine hydrochloride","volume":"222","author":"Scott","year":"1972","journal-title":"JAMA"},{"key":"10.1111\/bjd.12954-BIB0019|bjd12954-cit-0019","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/1097-0142(197307)32:1<18::AID-CNCR2820320103>3.0.CO;2-Q","article-title":"Complete remissions of mycosis fungoides lymphoma induced by topical nitrogen mustard (HN2). Control of delayed hypersensitivity to HN2 by desensitization and by induction of specific immunologic tolerance","volume":"32","author":"Scott","year":"1973","journal-title":"Cancer"},{"key":"10.1111\/bjd.12954-BIB0020|bjd12954-cit-0020","first-page":"681","article-title":"A 10-year experience with topical mechlorethamine for mycosis fungoides: comparison with patients treated by total-skin electron-beam radiation therapy","volume":"63","author":"Vonderheid","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"10.1111\/bjd.12954-BIB0021|bjd12954-cit-0021","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/archderm.1982.01650160024015","article-title":"The treatment of mycosis fungoides with ointment-based mechlorethamine","volume":"118","author":"Price","year":"1982","journal-title":"Arch Dermatol"},{"key":"10.1111\/bjd.12954-BIB0022|bjd12954-cit-0022","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1001\/archderm.141.9.1117","article-title":"Treatment of early-stage mycosis fungoides with twice-weekly applications of mechlorethamine and topical corticosteroids: a prospective study","volume":"141","author":"Quatrebarbes","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1111\/bjd.12954-BIB0023|bjd12954-cit-0023","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1001\/archderm.1982.01650150012011","article-title":"Treatment of mycosis fungoides: total-skin electron-beam irradiation versus topical mechlorethamine therapy","volume":"118","author":"Hamminga","year":"1982","journal-title":"Arch Dermatol"},{"key":"10.1111\/bjd.12954-BIB0024|bjd12954-cit-0024","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S0190-9622(88)70223-6","article-title":"Topical mechlorethamine therapy for early stage mycosis fungoides","volume":"19","author":"Ramsay","year":"1988","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.12954-BIB0025|bjd12954-cit-0025","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1001\/archderm.1984.01650480047016","article-title":"Response of mycosis fungoides to topical chemotherapy with mechlorethamine","volume":"120","author":"Ramsay","year":"1984","journal-title":"Arch Dermatol"},{"key":"10.1111\/bjd.12954-BIB0026|bjd12954-cit-0026","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S0190-9622(89)70051-7","article-title":"Long-term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T cell lymphoma","volume":"20","author":"Vonderheid","year":"1989","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.12954-BIB0027|bjd12954-cit-0027","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3109\/09546634.2012.735638","article-title":"Long-term follow-up of early mycosis fungoides patients treated with narrowband ultraviolet B phototherapy","volume":"25","author":"Elcin","year":"2014","journal-title":"J Dermatolog Treat"},{"key":"10.1111\/bjd.12954-BIB0028|bjd12954-cit-0028","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1600-0781.2012.00662.x","article-title":"Phototherapy for hypopigmented mycosis fungoides in Asians","volume":"28","author":"Wongpraparut","year":"2012","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"10.1111\/bjd.12954-BIB0029|bjd12954-cit-0029","doi-asserted-by":"crossref","first-page":"474","DOI":"10.5021\/ad.2011.23.4.474","article-title":"Narrowband ultraviolet B phototherapy of early stage mycosis fungoides in Korean patients","volume":"23","author":"Jang","year":"2011","journal-title":"Ann Dermatol"},{"key":"10.1111\/bjd.12954-BIB0030|bjd12954-cit-0030","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2230.2011.04197.x","article-title":"Efficacy of narrowband ultraviolet B twice weekly for hypopigmented mycosis fungoides in Asians","volume":"37","author":"Kanokrungsee","year":"2012","journal-title":"Clin Exp Dermatol"},{"key":"10.1111\/bjd.12954-BIB0031|bjd12954-cit-0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000161114","article-title":"Treatment of early stages of mycosis fungoides with narrowband ultraviolet B. A clinical, histological and molecular evaluation of results","volume":"218","author":"Dereure","year":"2009","journal-title":"Dermatology"},{"key":"10.1111\/bjd.12954-BIB0032|bjd12954-cit-0036","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2340\/00015555-0283","article-title":"Narrowband UVB and PUVA in the treatment of mycosis fungoides: a retrospective study","volume":"87","author":"Ahmad","year":"2007","journal-title":"Acta Derm Venereol"},{"key":"10.1111\/bjd.12954-BIB0033|bjd12954-cit-0037","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1600-0781.2012.00683.x","article-title":"Narrowband UVB as an effective substitute for psoralen plus UVA: lessons from a psoralen shortage","volume":"28","author":"Drucker","year":"2012","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"10.1111\/bjd.12954-BIB0034|bjd12954-cit-0038","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1067\/mjd.2003.80","article-title":"Narrowband UVB and psoralen-UVA in the treatment of early-stage mycosis fungoides: a retrospective study","volume":"48","author":"Diederen","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.12954-BIB0035|bjd12954-cit-0039","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/j.1468-3083.2006.01635.x","article-title":"Narrowband UVB phototherapy for early-stage mycosis fungoides: evaluation of clinical and histopathological changes","volume":"20","author":"Gokdemir","year":"2006","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/bjd.12954-BIB0036|bjd12954-cit-0040","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1001\/archderm.141.3.305","article-title":"Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy","volume":"141","author":"Querfeld","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1111\/bjd.12954-BIB0037|bjd12954-cit-0041","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.12254","article-title":"Localized conventional radiotherapy in the treatment of mycosis fungoides: our experience in 100 patients","author":"Piccinno","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/bjd.12954-BIB0038|bjd12954-cit-0042","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0360-3016(97)00553-1","article-title":"Local superficial radiotherapy in the management of minimal stage IA cutaneous T-cell lymphoma (mycosis fungoides)","volume":"40","author":"Wilson","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1111\/bjd.12954-BIB0039|bjd12954-cit-0043","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1111\/j.1365-2133.2011.10728.x","article-title":"Radiation therapy in the management of unilesional primary cutaneous T-cell lymphomas","volume":"166","author":"Chan","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.12954-BIB0040|bjd12954-cit-0044","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0360-3016(98)00218-1","article-title":"Radiotherapy for unilesional mycosis fungoides","volume":"42","author":"Micaily","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1111\/bjd.12954-BIB0041|bjd12954-cit-0045","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/0360-3016(83)90321-8","article-title":"Palliative radiation treatment of cutaneous mycosis fungoides - a dose response","volume":"9","author":"Cotter","year":"1983","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1111\/bjd.12954-BIB0042|bjd12954-cit-0046","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ijrobp.2008.06.1918","article-title":"Low-dose palliative radiotherapy for cutaneous B- and T-cell lymphomas","volume":"74","author":"Neelis","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1111\/bjd.12954-BIB0043|bjd12954-cit-0047","first-page":"1","article-title":"Cutaneous lymphomas - radiotherapeutic strategies","volume":"39","author":"Wilson","year":"2006","journal-title":"Front Radiat Ther Oncol"},{"key":"10.1111\/bjd.12954-BIB0044|bjd12954-cit-0048","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0190-9622(00)90140-3","article-title":"Unilesional cutaneous T-cell lymphoma: clinical features, therapy, and follow-up of 10 patients with a treatment-responsive mycosis fungoides variant","volume":"42","author":"Heald","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.12954-BIB0045|bjd12954-cit-0049","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1159\/000051542","article-title":"Unilesional mycosis fungoides: a study of seven cases","volume":"201","author":"Hodak","year":"2000","journal-title":"Dermatology"},{"key":"10.1111\/bjd.12954-BIB0046|bjd12954-cit-0050","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","article-title":"Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)","volume":"109","author":"Duvic","year":"2007","journal-title":"Blood"},{"key":"10.1111\/bjd.12954-BIB0047|bjd12954-cit-0051","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1111\/bjd.12954-BIB0048|bjd12954-cit-0052","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","article-title":"Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma","volume":"28","author":"Whittaker","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1111\/bjd.12954-BIB0049|bjd12954-cit-0531","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.ejca.2012.08.017","article-title":"Panobinostat activity in both bexarotene-exposed and -naive patients with refractory cutaneous T-cell lymphoma: results of a phase II trial","volume":"49","author":"Duvic","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1111\/bjd.12954-BIB0050|bjd12954-cit-0054","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1200\/JCO.2008.21.6150","article-title":"Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma","volume":"27","author":"Piekarz","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1111\/bjd.12954-BIB0051|bjd12954-cit-0055","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0190-9622(03)01591-3","article-title":"Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients","volume":"49","author":"Zackheim","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.12954-BIB0052|bjd12954-cit-0056","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0190-9622(96)80062-4","article-title":"Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: results in twenty-nine patients","volume":"34","author":"Zackheim","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.12954-BIB0053|bjd12954-cit-0053","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1056\/NEJM198912283212603","article-title":"A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides","volume":"321","author":"Kaye","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1111\/bjd.12954-BIB0054|bjd12954-cit-0057","doi-asserted-by":"crossref","first-page":"5748","DOI":"10.1158\/1078-0432.CCR-11-0556","article-title":"Multicenter phase II trial of temozolomide in mycosis fungoides\/S\u00e9zary syndrome: correlation with O6-methylguanine-DNA methyltransferase and mismatch repair proteins","volume":"17","author":"Querfeld","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1111\/bjd.12954-BIB0055|bjd12954-cit-0058","first-page":"1283","article-title":"Phase II trial of temozolomide in patients with pretreated cutaneous T-cell lymphoma","volume":"90","author":"Tani","year":"2005","journal-title":"Haematologica"},{"key":"10.1111\/bjd.12954-BIB0056|bjd12954-cit-0059","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1182\/blood-2002-09-2802","article-title":"Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides\/S\u00e9zary syndrome","volume":"101","author":"Lundin","year":"2003","journal-title":"Blood"},{"key":"10.1111\/bjd.12954-BIB0057|bjd12954-cit-0060","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3324\/haematol.11127","article-title":"Low-dose intermittent alemtuzumab in the treatment of S\u00e9zary syndrome: clinical and immunologic findings in 14 patients","volume":"92","author":"Bernengo","year":"2007","journal-title":"Haematologica"},{"key":"10.1111\/bjd.12954-BIB0058|bjd12954-cit-0061","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1182\/blood-2011-11-390211","article-title":"Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"119","author":"Horwitz","year":"2012","journal-title":"Blood"},{"key":"10.1111\/bjd.12954-BIB0059|bjd12954-cit-0062","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2007.11.4207","article-title":"Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"25","author":"Zinzani","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1111\/bjd.12954-BIB0060|bjd12954-cit-0063","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1002\/cncr.21449","article-title":"Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients","volume":"104","author":"Marchi","year":"2005","journal-title":"Cancer"},{"key":"10.1111\/bjd.12954-BIB0061|bjd12954-cit-0064","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/annonc\/mdp508","article-title":"Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome","volume":"21","author":"Zinzani","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1111\/bjd.12954-BIB0062|bjd12954-cit-0065","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1200\/JCO.1991.9.4.565","article-title":"Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease","volume":"9","author":"Cummings","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1111\/bjd.12954-BIB0063|bjd12954-cit-0066","first-page":"CD008908","article-title":"Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphoma","volume":"8","author":"Schlaak","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl. 2","key":"10.1111\/bjd.12954-BIB0064|bjd12954-cit-0067","doi-asserted-by":"crossref","first-page":"ii72","DOI":"10.1093\/annonc\/mdn095","article-title":"Primary cutaneous lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up","volume":"19","author":"Dummer","year":"2008","journal-title":"Ann Oncol"},{"issue":"Suppl. 5","key":"10.1111\/bjd.12954-BIB0065|bjd12954-cit-0068","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/annonc\/mdq183","article-title":"Primary cutaneous lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up","volume":"21","author":"Willemze","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1111\/bjd.12954-BIB0066|bjd12954-cit-0069","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","article-title":"Clinical end points and response criteria in mycosis fungoides and S\u00e9zary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer","volume":"29","author":"Olsen","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1111\/bjd.12954-BIB0067|bjd12954-cit-0070","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.2105\/AJPH.89.8.1240","article-title":"Twenty-year trends in the reported incidence of mycosis fungoides and associated mortality","volume":"89","author":"Weinstock","year":"1999","journal-title":"Am J Public Health"},{"key":"10.1111\/bjd.12954-BIB0068|bjd12954-cit-0071","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1002\/cncr.22252","article-title":"Significant impact of cutaneous T-cell lymphoma on patients' quality of life: results of a 2005 National Cutaneous Lymphoma Foundation Survey","volume":"107","author":"Demierre","year":"2006","journal-title":"Cancer"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjd.12954","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/bjd.12954\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,26]],"date-time":"2024-05-26T19:57:12Z","timestamp":1716753432000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/170\/5\/1015\/6614721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":68,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"URL":"https:\/\/doi.org\/10.1111\/bjd.12954","relation":{},"ISSN":["0007-0963"],"issn-type":[{"value":"0007-0963","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]}}}